The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Management of glioblastoma: State of the art and future directions
Open accessAbstract
Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for patients with this disease is poor, with a median survival of <2 years. There is a slight predominance in males, and incidence increases with age. The standard approach to therapy in the newly diagnosed setting includes surgery followed by concurrent radiotherapy with temozolomide and further adjuvant temozolomide. Tumor‐treating fields, delivering low‐intensity alternating electric fields, can also be given concurrently with adjuvant temozolomide. At recurrence, there is no standard of care; however, surgery, radiotherapy, and systemic therapy with chemotherapy or bevacizumab are all potential options, depending on the patient's circumstances. Supportive and palliative care remain important considerations throughout the disease course in the multimodality approach to management. The recently revised classification of glioblastoma based on molecular profiling, notably isocitrate dehydrogenase ( IDH ) mutation status, is a result of enhanced understanding of the underlying pathogenesis of disease. There is a clear need for better therapeutic options, and there have been substantial efforts exploring immunotherapy and precision oncology approaches. In contrast to other solid tumors, however, biological factors, such as the blood‐brain barrier and the unique tumor and immune microenvironment, represent significant challenges in the development of novel therapies. Innovative clinical trial designs with biomarker‐enrichment strategies are needed to ultimately improve the outcome of patients with glioblastoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
Ostrom, Q. T., Gittleman, H., Farah, P., Ondracek, A., Chen, Y., Wolinsky, Y., Stroup, N. E., Kruchko, C., & Barnholtz-Sloan, J. S. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not151 · Cited by 11,994
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Structural and functional features of central nervous system lymphatic vessels
Louveau, A., Smirnov, I., Keyes, T. J., Eccles, J. D., Rouhani, S. J., Peske, J. D., Derecki, N. C., Castle, D., Mandell, J. W., Lee, K. S., et al. (2015) · Nature · doi:10.1038/nature14432 · Cited by 4,413
Cited by
The role of m6A modification in the biological functions and diseases
Jiang, X., Liu, B., Nie, Z., Duan, L., Xiong, Q., Jin, Z., Yang, C., & Chen, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00450-x · Cited by 2,335
Glioma targeted therapy: insight into future of molecular approaches
Yang, K., Wu, Z., Zhang, H., Zhang, N., Wu, W., Wang, Z., Dai, Z., Zhang, X., Zhang, L., Peng, Y., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01513-z · Cited by 704
Emerging therapies for glioblastoma: current state and future directions
Rong, L., Li, N., & Zhang, Z. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02349-7 · Cited by 510
Clinical practice guidelines for the management of adult diffuse gliomas
Jiang, T., Nam, D.-H., Ram, Z., Poon, W.-S., Wang, J., Boldbaatar, D., Mao, Y., Ma, W., Mao, Q., You, Y., et al. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.050 · Cited by 431
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Glioblastoma: clinical presentation, diagnosis, and management
McKinnon, C., Nandhabalan, M., Murray, S. A., & Plaha, P. (2021) · BMJ · doi:10.1136/bmj.n1560 · Cited by 391
Prognostic and Predictive Biomarkers in Gliomas
Śledzińska, P., Bebyn, M. G., Furtak, J., Kowalewski, J., & Lewandowska, M. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910373 · Cited by 340
Immunotherapy for glioblastoma: current state, challenges, and future perspectives
Liu, Y., Zhou, F., Ali, H., Lathia, J. D., & Chen, P. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01226-x · Cited by 336
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM)
Yalamarty, S. S. K., Filipczak, N., Li, X., Subhan, M. A., Parveen, F., Ataide, J. A., Rajmalani, B. A., & Torchilin, V. P. (2023) · Cancers · doi:10.3390/cancers15072116 · Cited by 293
Glioblastoma Therapy: Past, Present and Future
Obrador, E., Moreno-Murciano, P., Oriol-Caballo, M., López-Blanch, R., Pineda, B., Gutiérrez-Arroyo, J., Loras, A., Gonzalez-Bonet, L., Martinez-Cadenas, C., Estrela, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052529 · Cited by 271
Crosstalk between circRNAs and the PI3K/AKT signaling pathway in cancer progression
Xue, C., Li, G., Lu, J., & Li, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00788-w · Cited by 268
Verdugo, E., Puerto, I., & Medina, M. Á. (2022) · Cancer Communications · doi:10.1002/cac2.12361 · Cited by 253
Zhan, Q., Yi, K., Cui, X., Li, X., Yang, S., Wang, Q., Fang, C., Tan, Y., Li, L., Xu, C., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac071 · Cited by 103
Engineered exosomes with enhanced stability and delivery efficiency for glioblastoma therapy
Wang, Y., Huo, Y., Zhao, C., Liu, H., Shao, Y., Zhu, C., An, L., Chen, X., & Chen, Z. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.02.015 · Cited by 84
Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer
Sharma, M., Bakshi, A. K., Mittapelly, N., Gautam, S., Marwaha, D., Rai, N., Singh, N., Tiwari, P., Agarwal, N., Kumar, A., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.007 · Cited by 84
Role of microRNAs in glioblastoma
Chen, M., Medarova, Z., & Moore, A. (2021) · Oncotarget · doi:10.18632/oncotarget.28039 · Cited by 84
(2023) · doi:10.1016/j.mtbio.2023.100612 · Cited by 71
Wang, L., Shi, Y., Jiang, J., Li, C., Zhang, H., Zhang, X., Jiang, T., Wang, L., Wang, Y., & Feng, L. (2022) · Small · doi:10.1002/smll.202203678 · Cited by 71
VRK1 as a synthetic lethal target in VRK2 promoter-methylated cancers of the nervous system
So, J., Mabe, N. W., Englinger, B., Chow, K.-H., Moyer, S. M., Yerrum, S., Trissal, M. C., Marques, J. G., Kwon, J. J., Shim, B., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.158755 · Cited by 45
Wang, Y., Wang, X., Wang, K., Qi, J., Zhang, Y., Wang, X., Zhang, L., Zhou, Y., Gu, L., Yu, R., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02728-8 · Cited by 55
Glioblastoma-cortical organoids recapitulate cell state heterogeneity and intercellular transfer
Mangena, V., Chanoch-Myers, R., Sartore, R., Paulsen, B., Gritsch, S., Weisman, H., Hara, T., Breakefield, X. O., Breyne, K., Regev, A., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1336 · Cited by 49
MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40
Yang, J., Luly, K. M., & Green, J. J. (2023) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1853 · Cited by 40
Liu, Y., Tang, Q., Tao, Q., Dong, H., Shi, Z., & Zhou, L. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.024 · Cited by 18
The Role of Micro RNAs in Regulating PI3K/AKT Signaling Pathways in Glioblastoma
Ghaffarian Zirak, R., Tajik, H., Asadi, J., Hashemian, P., & Javid, H. (2022) · Iranian Journal of Pathology · doi:10.30699/ijp.2022.539029.2726 · Cited by 17
Prabhudesai, S., Wang, N. C., Ahluwalia, V., Huan, X., Bapuraj, J. R., Banovic, N., & Rao, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.740353 · Cited by 13
Long Non-coding RNA KTN1-AS1 Targets miR-505 to Promote Glioblastoma Progression
Guo, K., Fang, L., Li, M., Li, A., & Liu, N. (2023) · Behavioural Neurology · doi:10.1155/2023/4190849 · Cited by 6
Metadata
- Authors
- Tan, A. C., Ashley, D. M., López, G. Y., Malinzak, M., Friedman, H. S., & Khasraw, M.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2020-06
- Volume
- 70
- Issue
- 4
- Pages
- 299-312
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W3031224726
- Cited by
- 1,972
- References
- 143
- FWCI
- 114.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.